GKOS - Glaukos Corporation Stock Price, News & Analysis

$24.50 -0.85 (-3.35 %)
(As of 11/23/2017 04:10 AM ET)
Previous Close$25.35
Today's Range$23.44 - $25.45
52-Week Range$23.44 - $52.49
Volume1.92 million shs
Average Volume640,727 shs
Market Capitalization$876.23 million
P/E Ratio211.25
Dividend YieldN/A
Beta1.25

About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation logoGlaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.


Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GKOS
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio6.93%
Quick Ratio6.48%

Price-To-Earnings

Trailing P/E Ratio211.25
Forward P/E Ratio-816.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$114.40 million
Price / Sales7.40
Cash Flow$0.27 per share
Price / Cash89.98
Book Value$3.82 per share
Price / Book6.41

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.04)
Net Income$4.52 million
Net Margins-0.64%
Return on Equity3.50%
Return on Assets3.05%

Miscellaneous

Employees264
Outstanding Shares34,560,000

Frequently Asked Questions for Glaukos Corporation (NYSE:GKOS)

What is Glaukos Corporation's stock symbol?

Glaukos Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos Corporation's earnings last quarter?

Glaukos Corporation (NYSE:GKOS) released its earnings results on Tuesday, November, 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.02) by $0.06. The medical instruments supplier had revenue of $40.41 million for the quarter, compared to the consensus estimate of $38.69 million. Glaukos Corporation had a positive return on equity of 3.50% and a negative net margin of 0.64%. Glaukos Corporation's quarterly revenue was up 36.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share. View Glaukos Corporation's Earnings History.

When will Glaukos Corporation make its next earnings announcement?

Glaukos Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Glaukos Corporation.

Where is Glaukos Corporation's stock going? Where will Glaukos Corporation's stock price be in 2017?

6 brokerages have issued 12 month price targets for Glaukos Corporation's stock. Their forecasts range from $38.00 to $60.00. On average, they expect Glaukos Corporation's share price to reach $47.50 in the next year. View Analyst Ratings for Glaukos Corporation.

What are Wall Street analysts saying about Glaukos Corporation stock?

Here are some recent quotes from research analysts about Glaukos Corporation stock:

  • 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (11/13/2017)
  • 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)

Who are some of Glaukos Corporation's key competitors?

Who are Glaukos Corporation's key executives?

Glaukos Corporation's management team includes the folowing people:

  • William J. Link Ph.D., Independent Chairman of the Board (Age 71)
  • Thomas William Burns, President, Chief Executive Officer and Director (Age 56)
  • Joseph E. Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development (Age 41)
  • Chris M. Calcaterra, Chief Commercial Officer and Chief Operating Officer (Age 56)
  • L. Jay Katz, Chief Medical Officer
  • Mark J. Foley, Independent Director (Age 51)
  • David F. Hoffmeister, Independent Director (Age 62)
  • Gilbert H. Kliman M.D., Independent Director (Age 58)
  • Jonathan Todd Silverstein J.D., Independent Director (Age 50)
  • Marc A. Stapley, Independent Director (Age 46)

When did Glaukos Corporation IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who owns Glaukos Corporation stock?

Glaukos Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (9.68%), Bamco Inc. NY (6.35%), Gilder Gagnon Howe & Co. LLC (4.22%), Wells Fargo & Company MN (3.70%), Orbimed Advisors LLC (2.42%) and Peregrine Capital Management LLC (1.36%). Company insiders that own Glaukos Corporation stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos Corporation.

Who sold Glaukos Corporation stock? Who is selling Glaukos Corporation stock?

Glaukos Corporation's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Wells Fargo & Company MN, Gilder Gagnon Howe & Co. LLC, Columbia Partners L L C Investment Management, Russell Investments Group Ltd., First Trust Advisors LP, GSA Capital Partners LLP and Dupont Capital Management Corp. Company insiders that have sold Glaukos Corporation company stock in the last year include Chris M Calcaterra, Orbimed Advisors Llc, Richard L Harrison and Thomas William Burns. View Insider Buying and Selling for Glaukos Corporation.

Who bought Glaukos Corporation stock? Who is buying Glaukos Corporation stock?

Glaukos Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Janus Henderson Group PLC, Peregrine Capital Management LLC, Artisan Partners Limited Partnership, Schwab Charles Investment Management Inc., Granite Investment Partners LLC, Strs Ohio and Iguana Healthcare Management LLC. Company insiders that have bought Glaukos Corporation stock in the last two years include Aimee S Weisner and Richard L Harrison. View Insider Buying and Selling for Glaukos Corporation.

How do I buy Glaukos Corporation stock?

Shares of Glaukos Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos Corporation's stock price today?

One share of Glaukos Corporation stock can currently be purchased for approximately $24.50.

How big of a company is Glaukos Corporation?

Glaukos Corporation has a market capitalization of $876.23 million and generates $114.40 million in revenue each year. The medical instruments supplier earns $4.52 million in net income (profit) each year or ($0.04) on an earnings per share basis. Glaukos Corporation employs 264 workers across the globe.

How can I contact Glaukos Corporation?

Glaukos Corporation's mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos Corporation (GKOS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Glaukos Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Glaukos Corporation (NYSE:GKOS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $47.50 (93.88% upside)

Consensus Price Target History for Glaukos Corporation (NYSE:GKOS)

Price Target History for Glaukos Corporation (NYSE:GKOS)

Analysts' Ratings History for Glaukos Corporation (NYSE:GKOS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017BMO Capital MarketsLower Price TargetOutperform$40.00 -> $38.00N/AView Rating Details
11/13/2017StephensReiterated RatingOverweight$47.00 -> $40.00N/AView Rating Details
11/7/2017Cantor FitzgeraldReiterated RatingBuy$60.00N/AView Rating Details
9/15/2017Piper Jaffray CompaniesReiterated RatingPositive -> Buy$38.00HighView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuyHighView Rating Details
8/3/2017Roth CapitalLower Price TargetBuy$60.00 -> $54.00HighView Rating Details
10/27/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
3/2/2016J P Morgan Chase & CoLower Price TargetOverweight$32.00 -> $28.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Glaukos Corporation (NYSE:GKOS)

Earnings by Quarter for Glaukos Corporation (NYSE:GKOS)

Earnings History by Quarter for Glaukos Corporation (NYSE GKOS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018        
11/7/2017Q3 2017($0.02)$0.04$38.69 million$40.41 millionViewN/AView Earnings Details
3/1/2017Q416$0.00$0.00$29.49 million$33.17 millionViewListenView Earnings Details
11/10/2016Q316($0.01)$0.03$27.21 million$29.60 millionViewN/AView Earnings Details
8/1/2016Q216($0.04)$0.06$24.45 million$28.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Glaukos Corporation (NYSE:GKOS)
Current Year EPS Consensus Estimate: $-0.03 EPS
Next Year EPS Consensus Estimate: $0.12 EPS

Dividends

Dividend History for Glaukos Corporation (NYSE:GKOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Glaukos Corporation (NYSE GKOS)

Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 93.07%
Insider Trades by Quarter for Glaukos Corporation (NYSE:GKOS)
Insider Trades by Quarter for Glaukos Corporation (NYSE:GKOS)

Insider Trades by Quarter for Glaukos Corporation (NYSE GKOS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Thomas William BurnsCEOSell73,788$41.36$3,051,871.68View SEC Filing  
9/5/2017Orbimed Advisors LlcDirectorSell580,200$38.73$22,471,146.00View SEC Filing  
9/5/2017Thomas William BurnsCEOSell1,212$41.25$49,995.00View SEC Filing  
8/17/2017Orbimed Advisors LlcDirectorSell325,000$37.93$12,327,250.00View SEC Filing  
3/14/2017Orbimed Advisors LlcDirectorSell382,538$45.33$17,340,447.54View SEC Filing  
2/2/2017Thomas William BurnsCEOSell50,000$42.58$2,129,000.00View SEC Filing  
1/13/2017Chris M CalcaterraInsiderSell18,136$40.01$725,621.36View SEC Filing  
1/13/2017Richard L HarrisonCFOSell20,634$40.00$825,360.00View SEC Filing  
1/9/2017Chris M CalcaterraInsiderSell20,000$38.02$760,400.00View SEC Filing  
1/9/2017Thomas William BurnsCEOSell40,000$37.60$1,504,000.00View SEC Filing  
1/6/2017Richard L HarrisonCFOSell20,634$35.58$734,157.72View SEC Filing  
11/17/2016William J Phd LinkDirectorSell30,000$33.78$1,013,400.00View SEC Filing  
11/15/2016Thomas William BurnsCEOSell200,120$33.68$6,740,041.60View SEC Filing  
10/24/2016Chris M CalcaterraInsiderSell20,000$36.01$720,200.00View SEC Filing  
10/20/2016Chris M CalcaterraInsiderSell40,000$34.76$1,390,400.00View SEC Filing  
8/12/2016Jonathan SilversteinDirectorSell292,938$33.69$9,869,081.22View SEC Filing  
8/3/2016Orbimed Advisors LlcDirectorSell425,000$30.59$13,000,750.00View SEC Filing  
7/27/2016Richard L HarrisonCFOSell10,000$35.01$350,100.00View SEC Filing  
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.78View SEC Filing  
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.00View SEC Filing  
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.00View SEC Filing  
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.00View SEC Filing  
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44View SEC Filing  
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.48View SEC Filing  
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.00View SEC Filing  
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.00View SEC Filing  
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.00View SEC Filing  
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40View SEC Filing  
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.00View SEC Filing  
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.00View SEC Filing  
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.40View SEC Filing  
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Glaukos Corporation (NYSE GKOS)

Source:
DateHeadline
Glaukos Is Now Oversold (GKOS)Glaukos Is Now Oversold (GKOS)
www.thestreet.com - November 21 at 7:06 PM
Glaukos Corporation (GKOS) versus Its Peers Head to Head ComparisonGlaukos Corporation (GKOS) versus Its Peers Head to Head Comparison
www.americanbankingnews.com - November 20 at 7:32 PM
Glaukos Corporation (GKOS) and Its Peers Head to Head SurveyGlaukos Corporation (GKOS) and Its Peers Head to Head Survey
www.americanbankingnews.com - November 20 at 5:24 PM
Reviewing Glaukos Corporation (GKOS) and Its PeersReviewing Glaukos Corporation (GKOS) and Its Peers
www.americanbankingnews.com - November 17 at 1:40 PM
BMO Capital Markets Cuts Glaukos Corporation (GKOS) Price Target to $38.00BMO Capital Markets Cuts Glaukos Corporation (GKOS) Price Target to $38.00
www.americanbankingnews.com - November 16 at 6:50 PM
ETFs with exposure to Glaukos Corp. : November 16, 2017ETFs with exposure to Glaukos Corp. : November 16, 2017
finance.yahoo.com - November 16 at 2:45 PM
Glaukos Corporation (GKOS) Raised to Hold at Zacks Investment ResearchGlaukos Corporation (GKOS) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - November 13 at 11:46 PM
Glaukos Corporations (GKOS) Overweight Rating Reaffirmed at StephensGlaukos Corporation's (GKOS) Overweight Rating Reaffirmed at Stephens
www.americanbankingnews.com - November 13 at 8:48 AM
Glaukos Corporation (GKOS) Receives Average Recommendation of "Buy" from BrokeragesGlaukos Corporation (GKOS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 12 at 4:22 PM
Glaukos (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call TranscriptGlaukos' (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript
www.msn.com - November 9 at 6:05 AM
Glaukos Corp to Host Earnings CallGlaukos Corp to Host Earnings Call
finance.yahoo.com - November 9 at 6:05 AM
Glaukos Corporation (GKOS) Tops Q3 EPS by 5c - StreetInsider.comGlaukos Corporation (GKOS) Tops Q3 EPS by 5c - StreetInsider.com
www.streetinsider.com - November 8 at 8:03 AM
Glaukos (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaGlaukos' (GKOS) CEO Thomas Burns on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 8:03 AM
Glaukos Corporation Announces Third Quarter 2017 Financial ResultsGlaukos Corporation Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 8:03 AM
Glaukos beats Street 3Q forecastsGlaukos beats Street 3Q forecasts
finance.yahoo.com - November 8 at 8:03 AM
Edited Transcript of GKOS earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of GKOS earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 8:03 AM
Glaukos Corporation (GKOS) Stock Rating Reaffirmed by Cantor FitzgeraldGlaukos Corporation (GKOS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 11:51 PM
Glaukos Corporation (GKOS) Posts  Earnings Results, Beats Estimates By $0.05 EPSGlaukos Corporation (GKOS) Posts Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - November 7 at 11:50 PM
Glaukos Corporation (GKOS) and Its Peers Critical ComparisonGlaukos Corporation (GKOS) and Its Peers Critical Comparison
www.americanbankingnews.com - November 7 at 7:22 PM
 Brokerages Expect Glaukos Corporation (GKOS) Will Post Quarterly Sales of $38.85 Million Brokerages Expect Glaukos Corporation (GKOS) Will Post Quarterly Sales of $38.85 Million
www.americanbankingnews.com - November 7 at 4:36 AM
 Brokerages Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.01 Per Share Brokerages Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - November 5 at 9:24 AM
Glaukos Announces Participation in Stifel 2017 Healthcare ConferenceGlaukos Announces Participation in Stifel 2017 Healthcare Conference
finance.yahoo.com - October 31 at 8:12 PM
ETFs with exposure to Glaukos Corp. : October 31, 2017ETFs with exposure to Glaukos Corp. : October 31, 2017
finance.yahoo.com - October 31 at 8:12 PM
Glaukos Corp. – Value Analysis (NYSE:GKOS) : October 31, 2017Glaukos Corp. – Value Analysis (NYSE:GKOS) : October 31, 2017
finance.yahoo.com - October 31 at 8:12 PM
Glaukos Corporation (GKOS) Scheduled to Post Earnings on TuesdayGlaukos Corporation (GKOS) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 1:34 PM
Glaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : October 30, 2017Glaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : October 30, 2017
finance.yahoo.com - October 30 at 7:57 PM
Glaukos Corporation to Release Third Quarter 2017 Financial Results after Market Close on November 7Glaukos Corporation to Release Third Quarter 2017 Financial Results after Market Close on November 7
finance.yahoo.com - October 25 at 2:27 AM
Meritech Capital Partners - BenzingaMeritech Capital Partners - Benzinga
www.benzinga.com - October 19 at 4:36 AM
Glaukos Corporation (GKOS) Given Consensus Rating of "Buy" by BrokeragesGlaukos Corporation (GKOS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 18 at 6:40 PM
Glaukos Corporation (GKOS) Expected to Post Quarterly Sales of $38.85 MillionGlaukos Corporation (GKOS) Expected to Post Quarterly Sales of $38.85 Million
www.americanbankingnews.com - October 18 at 2:36 AM
ETFs with exposure to Glaukos Corp. : October 16, 2017ETFs with exposure to Glaukos Corp. : October 16, 2017
finance.yahoo.com - October 16 at 3:46 PM
Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery - Business Wire (press release)Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery - Business Wire (press release)
www.businesswire.com - October 5 at 6:55 PM
Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away? - NasdaqWeakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away? - Nasdaq
www.nasdaq.com - October 5 at 6:55 PM
Glaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive SurgeryGlaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery
finance.yahoo.com - October 5 at 6:54 PM
Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away?Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away?
www.zacks.com - October 5 at 8:22 AM
Should You Be Holding Glaukos Corporation (GKOS) Right Now?Should You Be Holding Glaukos Corporation (GKOS) Right Now?
finance.yahoo.com - October 4 at 11:50 AM
Glaukos Corp. :GKOS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017Glaukos Corp. :GKOS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 2:03 PM
ETFs with exposure to Glaukos Corp. : October 2, 2017ETFs with exposure to Glaukos Corp. : October 2, 2017
finance.yahoo.com - October 2 at 2:03 PM
Head-To-Head Analysis: Glaukos Corporation (GKOS) vs. OBALON THERPTCS (OBLN)Head-To-Head Analysis: Glaukos Corporation (GKOS) vs. OBALON THERPTCS (OBLN)
www.americanbankingnews.com - September 28 at 9:38 AM
Glaukos Corporation (GKOS) Given Average Rating of "Buy" by BrokeragesGlaukos Corporation (GKOS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 23 at 4:38 PM
First Week of GKOS November 17th Options TradingFirst Week of GKOS November 17th Options Trading
www.thestreet.com - September 19 at 7:03 PM
Reviewing Stryker Corporation (SYK) & Glaukos Corporation (GKOS)Reviewing Stryker Corporation (SYK) & Glaukos Corporation (GKOS)
www.americanbankingnews.com - September 19 at 4:26 PM
Is It Too Late To Buy Glaukos Corporation (GKOS)? - Yahoo FinanceIs It Too Late To Buy Glaukos Corporation (GKOS)? - Yahoo Finance
finance.yahoo.com - September 16 at 12:43 AM
Glaukos Corp. breached its 50 day moving average in a Bearish Manner : GKOS-US : September 15, 2017Glaukos Corp. breached its 50 day moving average in a Bearish Manner : GKOS-US : September 15, 2017
finance.yahoo.com - September 15 at 7:40 PM
Glaukos Corporation (GKOS) Receives Buy Rating from StephensGlaukos Corporation (GKOS) Receives Buy Rating from Stephens
www.americanbankingnews.com - September 15 at 5:32 PM
Glaukos Corporation (GKOS) Price Target Lowered to $38.00 at Piper Jaffray CompaniesGlaukos Corporation (GKOS) Price Target Lowered to $38.00 at Piper Jaffray Companies
www.americanbankingnews.com - September 15 at 8:30 AM
Glaukos Corporation (GKOS) Stock Rating Reaffirmed by Stifel NicolausGlaukos Corporation (GKOS) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - September 14 at 9:50 PM
Glaukos Corporation (GKOS) Trims Q3 and FY Sales GuidanceGlaukos Corporation (GKOS) Trims Q3 and FY Sales Guidance
www.streetinsider.com - September 14 at 7:42 PM
Glaukos to Outline Growth Strategy at Investor DayGlaukos to Outline Growth Strategy at Investor Day
finance.yahoo.com - September 14 at 7:42 PM
Is It Too Late To Buy Glaukos Corporation (GKOS)?Is It Too Late To Buy Glaukos Corporation (GKOS)?
finance.yahoo.com - September 14 at 7:42 PM

Social Media

Financials

Chart

Glaukos Corporation (NYSE GKOS) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.